Sialic Acid on the Glycosylphosphatidylinositol Anchor Regulates PrP-mediated Cell Signalling and Prion Formation by Bate, Clive et al.
 1 
 Sialic Acid on the Glycosylphosphatidylinositol Anchor Regulates PrP-mediated Cell Signalling 
and Prion Formation 
Clive Bate
1
 William Nolan
1
 & Alun Williams
2
 
 
1 
Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, North 
Mymms, Herts, UK. AL9 7TA.  
2
 Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, UK. CB3 
OES. 
Running Title: Composition of GPI affects prion formation 
Corresponding Author; Dr Clive Bate, Tel: 01707 666550, Fax 01707 661464. E-mail: cbate@rvc.ac.uk 
Key words: cholesterol, glycosylphosphatidylinositols, phospholipase A2, prion, sialic acid 
 
SUMMARY 
The prion diseases occur following the conversion 
of the cellular prion protein (PrP
C
) into disease-
related isoforms (PrP
Sc
). In this study the role of 
the glycosylphosphatidylinositol (GPI) anchor 
attached to PrP
C
 in prion formation was examined 
using a cell painting technique. PrP
Sc
 formation in 
two prion-infected neuronal cell lines (ScGT1 and 
ScN2a cells), and in scrapie-infected primary 
cortical neurons, was increased following the 
introduction of PrP
C
. In contrast, PrP
C
 containing a 
GPI anchor from which the sialic acid had been 
removed (desialylated PrP
C
) was not converted to 
PrP
Sc
.  Furthermore, the presence of desialylated 
PrP
C 
inhibited the production of PrP
Sc
 within prion-
infected cortical neurons, ScGT1 and ScN2a cells.
 
 
The membrane rafts surrounding desialylated PrP
C
 
contained greater amounts of sialylated 
gangliosides and cholesterol than membrane rafts 
surrounding PrP
C
. Desialylated PrP
C
 was less 
sensitive to cholesterol depletion than PrP
C
 and 
was not released from cells by treatment with 
glimepiride. The presence of desialylated PrP
C
 in 
neurons caused the dissociation of cytoplasmic 
phospholipase A2 (cPLA2) from PrP-containing 
membrane rafts and reduced the activation of 
cPLA2. These findings show that the sialic acid 
moiety of the GPI attached to PrP
C
 modifies local 
membrane microenvironments that are important 
in PrP-mediated cell signalling and PrP
Sc
 
formation. These results suggest that 
pharmacological modification of GPI glycosylation 
might constitute a novel therapeutic approach to 
prion diseases. 
 
Introduction 
The prion diseases are fatal neurodegenerative 
disorders that include scrapie in sheep and goats, 
bovine spongiform encephalopathy in cattle and 
Creutzfeldt-Jakob disease in man. A key event in 
these diseases is the conversion of a normal host 
protein designated PrP
C
 into disease-associated 
isoforms (PrP
Sc
). In this conversion process a 
portion of PrP
C
 that is mostly -helix and random 
coil becomes refolded into a -pleated sheet in the 
PrP
Sc 
molecule (1). Although the presence of PrP
C
 
is essential for prion formation (2), not all cells that 
express PrP
C
 are permissive for PrP
Sc
 replication. 
The reasons why some cells that express PrP
C
 do 
not replicate PrP
Sc
 are not fully understood. 
Reports that the targeting of PrP
C
 to specific 
membranes is required for efficient PrP
Sc
 
formation (3,4) indicate that factors that affect the 
cellular targeting and intracellular trafficking of 
PrP
C
 are critical in determining PrP
Sc
 replication. 
 
The majority of PrP
C
 molecules are linked to 
membranes via a glycosylphosphatidylinositol 
(GPI) anchor (5). GPI anchors play a complex role 
in the regulation of cell membrane composition, 
cell signalling and protein trafficking (6). For 
example, the presence of a GPI anchor targets PrP
C
 
to specific membrane micro-domains called rafts 
that are required for efficient PrP
Sc
 formation (3,4). 
The role of the GPI anchor in prion diseases is 
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controversial as transgenic mice that produce 
anchorless PrP
C
 produce large amounts of soluble 
PrP
Sc
 (7), suggesting that the GPI anchor was not 
essential for PrP
Sc
 formation. In contrast, 
observations that neuronal cells producing 
anchorless PrP
C
 were resistant to scrapie infection 
(8), and that monoacylated PrP
C
 was not converted 
to PrP
Sc
 within neuronal cells (9), indicate that the 
GPI is a critical factor in facilitating membrane-
associated PrP
Sc
 formation.  
 
GPI-anchored molecules, including PrP
C
, are 
rapidly incorporated into living cells (10,11) and 
introducing PrP
C
 to prion infected cells by cell 
painting increased PrP
Sc
 formation (9). This 
technique was used to examine the role of specific 
GPI structures on PrP
C
 and PrP
Sc
 formation. The 
GPI anchor attached to PrP
C
 is unusual amongst 
mammalian GPIs in that it contains sialic acid (12). 
Neuraminidase digestion was used to produce a 
PrP
C
 with a GPI anchor lacking sialic acid 
(desialylated PrP
C
), a modification that could not 
be achieved by genetic manipulation methods (13). 
We report 3 major observations; firstly that 
desialylated PrP
C
 behaves differently from PrP
C
 
with regards to its effects on membrane 
composition and cell signalling, secondly that 
desialylated PrP
C
 is not converted to PrP
Sc
 and 
thirdly that desialylated PrP
C
 inhibits the 
conversion of endogenous PrP
C
 to PrP
Sc
. 
 
Experimental procedures 
 
Cell lines – Prion-infected ScN2a and ScGT1 cells 
were grown in Ham’s F12 medium containing 2 
mM glutamine and 2% foetal calf serum. To 
determine the effect of test preparations on PrP
Sc 
formation, ScN2a or ScGT1 cells were added to 6 
well plates, allowed to adhere overnight and then 
cultured in the presence or absence of test PrP
C
 
preparations. Cells were grown with daily changes 
of media (± PrP
C
 preparations) and the amounts of 
PrP
Sc
 were evaluated after 7 days. In other 
experiments ScGT1 and ScN2a cells were pre-
treated for 1 hour with control medium or 
desialylated PrP
C
 and then incubated with 
phospholipase A2-activating peptide (PLAP) 
(Bachem) for a further 1 hour. 
 
Primary neurons - Cortical neurons were 
prepared from the brains of mouse embryos (day 
15.5) derived from Prnp wild type
(+/+)
 and Prnp 
knockout
(0/0)
 mice after mechanical dissociation. 
Neurons (10
6
) were added to 6 well plates that had 
been coated with poly-L-lysine and incubated in 
Ham’s F12 medium containing 5% foetal calf 
serum for 2 hours. Cultures were shaken (600 rpm 
for 5 minutes) and non-adherent cells removed by 
2 washes in PBS. Neurons were grown in 
neurobasal medium (NBM) containing B27 
components and 5 ng/ml nerve growth factor 
(Sigma) for 10 days. Immunostaining showed that 
the cells were greater than 95% neurofilament 
positive. In some experiments neurons were pre-
treated for 24 hours with squalestatin 
(GlaxoSmithKline). The fate of PrP
C
 preparations 
was determined by incubating neurons with 10 ng 
PrP
C
 or desialylated PrP
C
. Cells were washed to 
remove unbound PrP
C
 and incubated in fresh 
culture medium for different time periods. For 
infection studies neurons from either Prnp
(0/0)
 or 
Prnp
(+/+)
 mice were pulsed with 1 ng PrP
Sc 
(derived 
from ScGT1 cells (14)) and then incubated with 10 
ng PrP
C
 or 10 ng desialylated PrP
C
. Media 
containing PrP
C
 preparations were replaced daily 
for 10 days and the amount of PrP
Sc
 in neurons was 
measured by enzyme-linked immunosorbent assay 
(ELISA). All experiments were performed in 
accordance with European regulations (European 
Community Council Directive, 1986, 56/609/EEC) 
and approved by the local authority veterinary 
service/ethical committee. 
 
Cell extracts - Treated cells were washed 3 times 
with ice cold PBS and homogenised in an 
extraction buffer containing 10 mM Triz-HCl pH 
7.4, 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet 
P-40, 0.5% sodium deoxycholate and 0.2% SDS at 
10
6
 cells/ml and nuclei and large fragments were 
removed by centrifugation (1000 x g for 5 
minutes). Mixed protease inhibitors (4-(2-
Aminoethyl) benzenesulfonyl fluoride 
hydrochloride, Aprotinin, Leupeptin, Bestatin, 
Pepstatin A and E-46) (Sigma) and a phosphatase 
inhibitor cocktail including PP1, PP2A, 
microcystin LR, cantharidin and p-
bromotetramisole (Sigma) were added to some 
membrane extracts. To determine the amount of 
PrP
Sc
 in cells extracts were digested with 1 µg/ml 
proteinase K for 1 hour at 37°C, heated to 95
o
C for 
5 minutes and tested in a PrP ELISA as described 
(9). 
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Isolation of detergent-resistant membranes 
(DRMs)/rafts - Cells were homogenised in an ice-
cold buffer containing 1% Triton X-100, 10 mM 
Triz-HCl pH 7.2, 100 mM NaCl, 10 mM EDTA 
and mixed protease inhibitors (10
6 
cells/ml) and 
nuclei and large fragments were removed by 
centrifugation (1000 x g for 5 minutes). The 
supernatant was incubated on ice for 60 minutes 
prior to further centrifugation (16,000 x g for 30 
minutes at 4
o
C). The detergent-soluble material 
(DSM) was reserved as the normal cell membrane. 
The insoluble DRMs were homogenised in 
extraction buffer (10 mM Triz-HCL pH 7.4, 10 
mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 
0.5% sodium deoxycholate and 0.2% SDS and 
mixed protease inhibitors. After further 
centrifugation (10 minutes at 16,000 x g) the 
supernatant was collected as the raft fraction.  
 
Sucrose density gradients - Cells were harvested 
with a Teflon scraper and homogenised in a buffer 
containing 250 mM sucrose, 10 mM Triz-HCl, pH 
7.2 and 1 mM EDTA, mixed protease inhibitors, 1 
mM dithiothreitol. Nuclei and cell fragments were 
removed by centrifugation (1000 x g for 5 
minutes). Membranes were washed by 
centrifugation at 16,000 x g for 20 minutes at 4
o
C 
and solubilised in an ice-cold buffer containing 1% 
Triton X-100, 10 mM Triz-HCl pH 7.2, 150 mM 
NaCl and 10 mM EDTA. 5, 10, 15, 20, 30 and 
40% sucrose solutions were prepared and layered 
to produce a gradient at 4
o
C. Solubilised 
membranes were layered on top and centrifuged at 
50,000 x g for 18 hours at 4°C. Serial 0.8 or 0.25 
ml volumes were collected from the bottom of 
gradients.  
 
Isolation of PrP
C
 - PrP
C
 molecules were isolated 
from murine GT1 neuronal cell membranes using a 
combination of immunoaffinity columns, size 
exclusion chromatography (Superdex) and reverse-
phase chromatography on C18 columns (Waters) 
as described (9). PrP
C
 was digested with 2 units/ml 
endoglycosidase F (PNGase) (Sigma) and/or 0.2 
units/ml neuraminidase (Clostridium perfringens - 
Sigma) for 2 hours at 37
o
C. Trifluoroacetic acid 
(TFA) was added (final concentration - 0.1%) and 
digested PrP
C
 was loaded onto C18 columns. 
Samples were eluted under a gradient of 
acetonitrile and water containing 0.1% TFA. 1 ml 
samples were collected, split into two and 
lyophilized. One sample was solubilised in an 
extraction buffer (as above) and tested in a PrP 
ELISA. PrP-containing fractions were solubilised 
in culture medium by sonication prior to use.  
 
Test PrP
Sc
 preparations. PrP
Sc
 preparations 
consisted of supernatants collected from ScGT1 
cells which were centrifuged (500 x g for 5 
minutes) to remove cell debris and concentrated 
using a 10 kDa filter (Sartorius Vivaspin). 
Preparations were digested with 1 µg/ml proteinase 
K for 1 hour at 37
O
C to remove PrP
C 
and the 
remaining protease-resistant PrP was measured by 
ELISA, see below. Samples were frozen at -20
o
C 
for storage. On the day of use, PrP
Sc
 preparations 
were diluted to 1 ng/ml in culture medium and 
sonicated before addition to cells. 
 
PrP ELISA - Maxisorb immunoplates (Nunc) 
were coated with mAb ICSM18 and blocked with 
5% milk powder. Samples were applied and 
detected with biotinylated mAb ICSM35, followed 
by extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenyl phosphate (Sigma). Absorbance was 
measured on a microplate reader at 405 nm and the 
amount of PrP in samples was calculated by 
reference to serial dilutions of recombinant murine 
PrP (Prionics).  
 
cPLA2 ELISA - Maxisorb immunoplates were 
coated with 0.5 µg/ml of mouse mAb anti-cPLA2, 
clone CH-7 (Upstate) and blocked. Samples were 
incubated for 1 hour and the amount of cPLA2 was 
detected using a goat polyclonal anti-cPLA2 
(Santa-Cruz Biotech) followed by biotinylated 
anti-goat IgG, extravidin-alkaline phosphatase and 
1 mg/ml 4-nitrophenyl phosphate. Absorbance was 
measured at 405 nm and the amount of cPLA2 
protein expressed in units, 100 units = amount of 
cPLA2 in extracts or immunoprecipitates from 10
6
 
untreated cells.  
 
Activated cPLA2 ELISA - The activation of 
cPLA2 is accompanied by phosphorylation of the 
505 serine residue which creates a unique epitope 
that was measured in an ELISA using an anti-
cPLA2 mAb (clone CH-7) combined with rabbit 
polyclonal anti-phospho-cPLA2 (Cell Signalling 
Technology) followed by biotinylated anti-rabbit 
IgG (Dako), extravidin-alkaline phosphatase and 
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1mg/ml 4-nitrophenyl phosphate). Absorbance was 
measured on a microplate reader at 405 nm. 
Results were expressed as “units activated cPLA2” 
with 100 units defined as the amount of activated 
cPLA2 in extracts derived from 10
6
 untreated cells. 
 
Isolation and analysis of GPIs – GPIs were 
isolated and analysed as described (13). Briefly, 
PrP
C
 preparations were digested with proteinase K 
(100 μg/ml) overnight at 37oC.  Digested products 
were mixed with water-saturated butanol. The 
butanol phase was collected and washed with 
water a further 3 times before being loaded onto 
C18 columns. GPIs were eluted from C18 columns 
under a gradient of propanol and water. The 
presence of phosphatidylinositol in GPIs was 
determined using mAb (5AB3-11) and specific 
glycans were detected with biotinylated lectins. 
Isolated GPIs bound to nitrocellulose membranes 
by dot blot and were blocked with 5% milk 
powder. Samples were probed with mAb 5AB3-11, 
biotinylated Sambucus nigra (S. nigra) lectin 
(detects terminal sialic acid residues bound α-2,6 
or α-2,3 to galactose), biotinylated concanavalin A 
(detects mannose) or biotinylated Ricinus 
Communis Agglutinin I (RCA I) (detects terminal 
galactose) (Vector Labs). Bound lectins were 
visualised using extravidin peroxidise and 
enhanced chemiluminescence. The mAb was 
visualised by incubation with a horseradish 
peroxidise conjugated anti-murine-IgM and 
chemiluminescence. In other studies GPIs were 
separated on silica gel 60 high performance thin 
layer chromatography (HPTLC) plates in a mixture 
of chloroform/methanol/water (10/10/3 v/v/v) and 
detected by mAb 5AB3-11. The concentrations of 
GPIs were measured by ELISA. Maxisorb 
immunoplates were coated with 0.5 µg/ml 
concanavalin A (binds mannose) and blocked with 
5% milk powder in PBS-tween.  Samples were 
added and any bound GPI was detected by the 
addition of mAb 5AB3-11 (15), followed by a 
biotinylated anti-mouse IgM (Sigma), extravidin-
alkaline phosphatase and 1mg/ml 4-nitrophenyl 
phosphate. Absorbance was measured on a 
microplate reader at 405 nm. 
 
Immunoprecipitations of PrP-specific rafts - 
Treated cells were homogenised in ice cold 1% 
Triton X-100, 10 mM Triz-HCl, pH 7.2, 100 mM 
NaCl, 10 mM EDTA at 10
6
 cells/ml. Cell debris 
was removed from by centrifugation (1000 x g for 
5 mins) and the supernatant incubated with a mAb 
to PrP (4F2) for 30 minutes at 4
o
C on rollers. 
Magnetic microbeads containing protein G 
(Miltenyi Biotech) were added (10 µl/ml) for 30 
minutes and protein G bound antibody complexes 
isolated using a µMACS magnetic system 
(Miltenyi Biotech) at 4
o
C. The amounts of 
sialylated gangliosides in precipitates were 
determined by diluting precipitates from 10
6
 cells 
in 1 ml carbonate buffer and plating in Maxisorb 
immunoplates overnight. Plates were blocked with 
5% milk powder in PBS-tween and sialylated 
gangliosides were detected by the addition of 
biotinylated S. nigra lectin followed by extravidin-
alkaline phosphatase and 1mg/ml 4-nitrophenyl 
phosphate. Absorbance was measured on a 
microplate reader at 405 nm. Gangliosides within 
immunoprecipitates were separated by HPTLC in a 
solvent containing chloroform/methanol/water 
(6/4/1). Plates were blocked and sialic acid 
containing gangliosides were detected by 
incubation with biotinylated S. nigra lectin, 
extravidin-peroxidase and chemiluminesence. 
 
Western Blot - Samples were dissolved in 50 μl of 
Laemmli buffer, boiled, and subjected to 
electrophoresis on a 15 % polyacrylamide gel. 
Proteins were transferred onto a Hybond-P PVDF 
membrane (Amersham Biotech) by semi-dry 
blotting. Membranes were blocked using 10% milk 
powder in PBS containing 0.2 % Tween 20. PrP 
was detected by incubation with mAb ICSM18, β-
actin by mAb AC-74 (Sigma) and cPLA2 with 
mAb CH-7, followed by a secondary anti-mouse 
IgG conjugated to peroxidase. Bound antibody was 
visualised by chemiluminescence. 
 
Cholesterol and protein content - Cholesterol 
and protein content were determined in cell 
membrane extracts. Protein concentrations were 
measured using a micro-BCA protein assay kit 
(Pierce). The concentrations of cholesterol were 
measured using the Amplex Red cholesterol assay 
kit (Invitrogen). Cholesterol is oxidised by 
cholesterol oxidase to yield hydrogen peroxide 
which reacts with 10-acetyl-3, 7-
dihydroxyphenoxazine (Amplex Red reagent) to 
produce highly fluorescent resorufin. Fluorescence 
was measured by excitation at 550 nm and 
emission detection at 590 nm. The concentration of 
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cholesterol was calculated by reference to 
cholesterol standards. 
 
Statistical Analysis - Comparison of treatment 
effects was carried out using Student’s paired t-
tests, one-way and two-way ANOVA with 
Bonferroni’s post-hoc tests (IBM SPSS statistics 
20). Error values are standard deviation (SD) and 
significance was determined where P<0.01. 
Correlations between data sets were analysed using 
Pearson’s bivariate coefficient (IBM SPSS 
statistics 20). 
 
Results 
 
Deglycosylated PrP
C
 is converted to PrP
Sc
 – 
Initial studies were performed to determine 
whether the N-linked glycans that are attached to 
PrP
C
 affect PrP
Sc
 formation in ScGT1 cells. N-
linked glycans were removed from PrP
C
 by 
digestion with PNGase (16) (Figure 1A) and 
deglycosylated PrP
C
 was isolated on C18 columns 
(Figure 1B). The addition of PrP
C
 or PNGase-
digested PrP
C
 (deglycosylated PrP
C
) increased the 
PrP
Sc
 content of ScGT1 cells in a dose-dependent 
manner (Figure 1C); there were no significant 
differences in the amounts of PrP
Sc
 in cells 
incubated with PrP
C 
or with deglycosylated PrP
C
. 
Similarly, the addition of 10 ng deglycosylated 
PrP
C
 increased the amount of PrP
Sc
 in ScN2a cells 
(4.7 ng PrP
Sc
/10
6
 cells ± 1.1 compared with 1.5 ng 
PrP
Sc
 ± 0.7, n=15, P<0.05). As the absence of N-
linked glycans did not significantly affect PrP
Sc
 
formation in these cells all the following 
experiments were performed with deglycosylated 
PrP
C
 preparations. 
 
Sialic acid on the GPI anchor of PrP
C
 is 
necessary for PrP
Sc
 formation - The GPI anchor 
attached to PrP
C
 is unusual for mammalian GPIs in 
that it contains sialic acid as first described by 
Stahl and colleagues (12) and illustrated in Figure 
2A. To confirm the presence of sialic acid in our 
PrP
C
 preparations, GPIs were isolated from PrP
C
 
and desialylated PrP
C
 (neuraminidase-digested) by 
reverse phase chromatography (Figure 2B). GPIs 
derived from PrP
C
 and desialylated PrP
C
 eluted at 
different concentrations of propanol. HPTLC 
analysis confirmed that neuraminidase digestion 
altered the migration of the GPI isolated from PrP
C
 
consistent with the loss of sialic acid (Figure 2C). 
Isolated GPIs were blotted onto nitrocellulose 
membranes and probed with mAb 5AB3-11 and 
biotinylated lectins. The digestion of PrP
C
 with 
neuraminidase did not affect the binding of mAb 
5AB3-11 (binds to phosphatidylinositol) or 
concanavalin A (binds to mannose) to the GPIs 
showing that similar amounts of GPIs were added 
to blots. S. nigra lectin (which reacts with terminal 
sialic acid bound either α-2,6 or α-2,3 to galactose) 
bound to GPIs isolated from PrP
C
, but not to GPIs 
derived from neuraminidase-digested PrP
C
 
indicating that sialic acid had been removed 
(Figure 2D). The lectin RCA I bound to 
neuraminidase-digested GPIs indicating that 
terminal galactose had been exposed.  
 
The observation that PrP
Sc
 does not replicate in 
Prnp
(0/0)
 neurons (14) allowed us to examine 
whether desialylated PrP
C
 was converted to PrP
Sc
. 
Both PrP
C
 and desialylated PrP
C
 bound readily to 
recipient Prnp
(0/0)
 neurons; following the addition 
of 10 ng PrP
C
 preparations for 2 hours there was no 
significant difference in the amounts of PrP
C
 and 
desialylated PrP
C
 bound (9.4 ng PrP
C
 ± 0.9 
compared with 9.7 ng ± 0.9, n=9, P=0.7). Neurons 
from Prnp
(0/0)
 mice were pulsed with 1 ng PrP
Sc 
for 
2 hours and incubated with culture media 
containing control medium, 10 ng PrP
C
 or 10 ng 
desialylated PrP
C
. Media containing the 
PrP
C
/desialylated PrP
C
 was replaced daily for 10 
days when the amounts of PrP
Sc
 in neurons were 
measured. We did not detect any PrP
Sc
 in neurons 
that had been pulsed with 1 ng PrP
Sc
 and incubated 
with control medium, suggesting that original 
inoculum was degraded by these neurons. 
However, PrP
Sc
 pulsed neurons incubated daily 
with 10 ng PrP
C
 contained 25.7 ng PrP
Sc
 ± 4.2, 
n=12 indicating that some of the added PrP
C
 was 
converted to PrP
Sc
. In contrast, no PrP
Sc
 was 
detected in neurons pulsed with 1 ng PrP
Sc
 and 
incubated daily with 10 ng desialylated PrP
C
 
indicating that it was not converted to PrP
Sc 
(Figure 
3A). Immunoblots confirmed the ELISA data and 
showed that PrP
Sc
 was formed in Prnp
(0/0)
 neurons 
pulsed with PrP
Sc
 and incubated daily with PrP
C
 
but not in neurons pulsed with PrP
Sc
 and incubated 
daily with control medium or with desialylated 
PrP
C
 (Figure 3B). 
 
Desialylated PrP
C
 reduced PrP
Sc
 formation – 
Next, the effects of desialylated PrP
C
 on the 
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conversion of endogenous PrP
C
 to PrP
Sc
 were 
determined For this study neurons derived from 
Prnp
(+/+) 
mice were pulsed with 1 ng PrP
Sc
 for 2 
hours and incubated for a further 10 days with 10 
ng PrP
C
 or 10 ng desialylated PrP
C
. Neurons pulsed 
with PrP
Sc 
and incubated in control medium 
contained 40.2 ng PrP
Sc
 ± 5.2, n=12.
 
The addition 
of PrP
C
 increased the amount of PrP
Sc
 in neurons to 
68.5 ng PrP
Sc
 ± 7.1, n=12, whereas the addition of 
desialylated PrP
C
 reduced the amount of PrP
Sc
 to 
5.2 ng/ml (Figure 4A&B) indicating that 
desialylated PrP
C
 suppressed the conversion of 
PrP
C
 to PrP
Sc
. Furthermore, when neurons from 
Prnp
(0/0)
 mice were pulsed with 1 ng PrP
Sc 
and 
incubated with 10 ng PrP
C
 or a mixture of 10 ng 
PrP
C
 and 10 ng desialylated PrP
C 
for 10 days the 
presence of desialylated PrP
C
 reduced PrP
Sc
 
production (Figure 4C). Similarly, the daily 
addition of desialylated PrP
C
 reduced the PrP
Sc
 
content of recipient ScN2a cells (Figure 4D) and 
ScGT1 cells (Figure 4E).   
 
Sialic acid on the GPI anchor affects the fate of 
PrP
C
 – To determine the mechanism(s) involved in 
desialylated PrP
C
-induced suppression of PrP
Sc
 
formation its properties in non-infected cells were 
examined. Both PrP
C
 and desialylated PrP
C
 bound 
readily to recipient Prnp
(0/0)
 neurons. The targeting 
of PrP
C
 to DRMs is necessary for efficient prion 
formation (4) and following the addition of 10 ng 
PrP
C
 preparations similar amounts of PrP
C
 and 
desialylated PrP
C
 were found within DRMs (8.2 ng 
PrP
C
 ± 0.9 compared with 8.1 ng desialylated PrP
C
 
± 1.2, n=9, P=0.7). PrP
C
 and desialylated PrP
C
 
were found within different membrane rafts; after 
Prnp
(0/0)
 neurons pulsed with 10 ng of PrP
C
 or 10 
ng desialylated PrP
C
 were homogenised in ice cold 
triton X-100 (which maintains the integrity of 
membrane rafts) and subjected to sucrose density 
gradient analysis, the desialylated PrP
C
 was found 
in lower density rafts than those containing PrP
C
 
(Figure 5A). These rafts were examined in detail 
after immunoprecipitation. Similar amounts of 
PrP
C
 and desialylated PrP
C
 were obtained in each 
precipitate (Figure 5B). However, the rafts isolated 
with PrP
C
 contained significantly less cholesterol 
than rafts surrounding desialylated PrP
C
 (Figure 
5C). HPTLC analysis of immunoprecipitates 
demonstrated that rafts containing desialylated 
PrP
C
 contained more sialylated gangliosides than 
did membranes surrounding PrP
C
 (Figure 5D). 
ELISA studies confirmed that rafts co-precipitated 
with desialylated PrP
C
 contained significantly more 
sialylated gangliosides than rafts co-precipitated 
with PrP
C
 (Figure 5E).  
Reducing cellular cholesterol concentrations 
destabilised some rafts resulting in the relocation 
of PrP
C
 from rafts to DSMs (4). Here we examined 
whether the targeting of desialylated PrP
C
 to 
DRMs was also sensitive to cholesterol depletion. 
Prnp
(0/0)
 neurons pre-treated with the cholesterol 
synthesis inhibitor squalestatin for 24 hours were 
pulsed with 10 ng PrP
C
 or 10 ng desialylated PrP
C
 
and DRMs (rafts) isolated. Whereas squalestatin 
reduced the amounts of PrP
C
 in rafts, desialylated 
PrP
C
 remained within rafts (Figure 6A). The 
concentrations of cholesterol within cell 
membranes were reduced by squalestatin in a dose-
dependent manner. There was a significant 
correlation between amounts of raft PrP
C
, but not 
desialylated PrP
C
, and concentrations of 
cholesterol in squalestatin-treated cells (Figure 
6B). Neurons incubated with PrP
C
/desialylated 
PrP
C
 were also treated with PI-PLC for 1 hour. 
While digestion with PI-PLC reduced the amounts 
of cell-associated desialylated PrP
C
 to less than 0.5 
ng (indicating that all desialylated PrP
C
 was 
expressed at the cell surface), 3.6 ng PrP
C
 ± 0.4 
remained cell-associated after PI-PLC digestion 
(Figure 6C). Increasing the concentration of PI-
PLC, or incubation period, did not affect the 
amounts of cell-associated PrP
C
 suggesting that 
there is a pool of PrP
C
 that is not expressed at the 
surface of neurons. As proteins with different GPI 
anchors traffic via different pathways (17,18), the 
effect of the GPI anchor on the fate of PrP
C
 within 
cells was investigated. Prnp
(0/0)
 neurons were 
pulsed with 10 ng of PrP
C
 preparations and the 
amounts of PrP
C
 measured at time points 
thereafter. Whereas PrP
C
 was rapidly cleared from 
neurons, and was absent after 48 hours, 
desialylated PrP
C
 remained in neurons for up to 96 
hours (Figure 6D). Some GPI-anchored proteins 
are released from cells following the glimepiride-
induced activation of an endogenous GPI-PLC 
(19,20).  Treatment with 5 µM glimepiride caused 
the release of PrP
C
 but not desialylated PrP
C
 
(Figure 6E). 
 
Desialylated PrP
C
 reduced the activation of 
cPLA2 in prion-infected cells – Since the 
concentration of cholesterol within cell membranes 
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affects PrP
Sc
 formation (4) the effects of PrP
C
 and 
desialylated PrP
C
 on cholesterol in prion-infected 
cells were also examined. The amount of 
cholesterol in ScGT1 cell membranes was 
significantly increased after incubation with 10 ng 
PrP
C
 (744 ng cholesterol/10
6 
cells ± 84 compared 
with 534 ± 48, n=9, P<0.05) or with 10 ng 
desialylated PrP
C
 (771 ng cholesterol/10
6 
cells ± 76 
compared with 534 ± 48, n=9, P<0.05). Critically 
there was no significant difference in the amounts 
of cholesterol between ScGT1 cells treated with 
PrP
C
 or with desialylated PrP
C
 (744 ng 
cholesterol/10
6 
cells ± 84 compared with 771 ± 76, 
n=9, P<0.36).  
 
As PrP
Sc
 formation is dependent upon the 
activation of cPLA2 (21) the effects of desialylated 
GPI on this enzyme were studied. The addition of 
25 ng desialylated PrP
C
 significantly reduced the 
amounts of activated cPLA2 in both ScN2a and 
ScGT1 cells (Table 1). However, desialylated PrP
C
 
did not affect PLAP-induced activation of cPLA2 
showing that it did not have a direct effect upon 
cPLA2. The possibility that the addition of PLAP 
could restore PrP
Sc
 formation in cells treated with 
desialylated PrP
C
 was investigated PrP
Sc
 was not 
detected in ScGT-1 cells treated with a 
combination of 25 ng desialylated PrP
C
 and 1 μM 
PLAP (PrP
Sc
<0.05 ng/10
6
 cells) showing that non-
selective activation of cPLA2 was not sufficient to 
reverse desialylated PrP
C
-induced suppression of 
PrP
Sc
 formation. 
 
The clustering of GPIs in the membrane that arises 
as a consequence of the self-aggregation of PrP
Sc
 
molecules can be mimicked by mAb-mediated 
cross-linkage of PrP
C
 which also activates cPLA2 
(22). When Prnp
(0/0)
 neurons were pulsed with PrP
C
 
or desialylated PrP
C
 and incubated with mAb 4F2 
cross-linkage of PrP
C
, but not desialylated PrP
C
, 
caused a dose-dependent increase in activated 
cPLA2 (Figure 7A). Furthermore, when Prnp
(+/+)
 
neurons were pulsed with desialylated PrP
C
 and 
incubated with mAb 4F2 to cross-link PrP
C
, the 
presence of desialylated PrP
C
 reduced activated 
cPLA2 in a dose-dependent manner (Figure 7B).  
 
Sialic acid on the GPI
 
anchor stabilised cPLA2 
within PrP-containing rafts - Upon activation 
cPLA2 migrates from the cytoplasm to rafts (9,23). 
Sucrose density gradients showed that in untreated 
ScGT1 cells most of the cPLA2 was in low density 
membranes (fractions 9 to 12) while in cells that 
had been incubated with 25 ng of desialylated PrP
C
 
a proportion of cPLA2 had relocated to fractions 4 
to 7 (Figure 8A). Immunoprecipitation studies 
showed that cPLA2 was found within PrP
Sc
-
containing rafts (9) raising the possibility that the 
sialic acid moiety on the GPI attached to PrP
C
 or 
PrP
Sc
 is required to capture cPLA2 within lipid 
rafts. This hypothesis was tested by treating 
Prnp
(+/+)
 neurons with 10 ng of PrP
C
 or 10 ng 
desialylated PrP
C
 followed by the cross-linkage of 
PrP
C
 by mAb 4F2. Although precipitates contained 
similar amounts of PrP
C
, the precipitates from 
neurons incubated with PrP
C
 contained more 
cPLA2 than precipitates from neurons containing 
desialylated PrP
C
 (Figure 8B). 
 
Discussion 
 
Recent studies suggest that differential 
glycosylation of the GPI anchor can affect the 
properties of some proteins, including protein 
structure (24), membrane localisation and 
intracellular trafficking (25). Here we show that 
sialic acid in the GPI affected the composition of 
the membranes surrounding PrP
C
, cell signalling 
and the conversion of PrP
C
 to PrP
Sc
. 
 
Desialylated PrP
C
 was created by the sequential 
digestion of PrP
C
 with a PNGase (to remove N-
linked glycans) followed by neuraminidase to 
remove sialic acid. The removal of N-linked 
glycans was necessary to show that the effects of 
the subsequent neuraminidase digestion was upon 
sialic acid contained within the GPI anchor, and 
not due to the removal of sialic acid contained 
within the N-linked glycans. Prnp
(0/0)
 neurons 
exposed to PrP
Sc
 demonstrated that while PrP
C
 was 
converted to PrP
Sc
, desialylated PrP
C
 was not. 
Consequently, the factors that prevented the 
conversion of desialylated PrP
C
 to PrP
Sc
 were 
examined. Both PrP
C
 and desialylated PrP
C
 bound 
to recipient cells, increased the concentrations of 
cholesterol in cell membranes and were targeted to 
rafts. However, membrane rafts are heterogeneous 
(26) and the composition of the GPI anchor is 
thought to target proteins to specific rafts. For 
example, PrP
C
 and Thy-1 have different GPI 
anchors and are targeted to different rafts (27) and 
replacing the GPI of PrP
C
 with that of Thy-1 
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altered the trafficking of PrP
C
 to apical membranes 
(28). Therefore it is possible that the differences in 
their GPIs direct PrP
C
 and desialylated PrP
C
 to 
different rafts and consequently their trafficking 
within cells.   
 
GPI-anchored proteins are surrounded by specific 
phospholipids, glycolipids and cholesterol that 
constitute a raft, the composition of which is 
dependent upon multiple interactions between the 
protein, glycans and membrane lipids (29). Thus, a 
change in the composition of the GPI anchor 
attached to a protein could affect the composition 
of the surrounding raft. This hypothesis is 
supported by observations that the composition of 
GPIs attached to Thy-1 differs from those attached 
to PrP
C
 (12,30) and the membranes surrounding 
these molecules have different lipid compositions 
(31). We hypothesise that the presence of sialic 
acid in the GPI has a direct effect upon the 
composition of the surrounding membrane rafts as 
illustrated in Figures 9A & B. Our observation that 
the rafts surrounding desialylated PrP
C
 contained 
more cholesterol and sialylated gangliosides than 
those surrounding PrP
C
 supported this hypothesis. 
In addition; treatment with glimepiride caused the 
release of PrP
C
, but not desialylated PrP
C
, 
suggesting that only PrP
C
 is associated with a raft 
containing endogenous GPI-PLC. How sialic acid 
affects the composition of rafts is unknown. One 
possibility is that the sialic acid contained within 
the GPI competes with gangliosides for sialic acid-
binding proteins within rafts. Thus the removal of 
sialic acid from the GPI would allow the 
incorporation of gangliosides, which are associated 
with the suppression of PrP
Sc
 formation (32), into 
rafts. Gangliosides help sequester cholesterol and 
stabilise rafts (33,34) especially in brain tissue 
(35). The increased amounts of gangliosides that 
surround desialylated PrP
C
 would be expected to 
form a raft containing more cholesterol, as was 
demonstrated in these experiments. The 
concentrations of cholesterol in cell membranes 
affects membrane rigidity and helps stabilise 
membrane rafts (36). We noted that desialylated 
PrP
C
 remained within rafts in cholesterol-depleted 
cells whereas PrP
C
 was relocated to DSMs, a 
finding indicating that the rafts surrounding 
desialylated PrP
C
 are more cholesterol dense and 
hence more resistant to cholesterol depletion than 
those surrounding PrP
C
. Such observations are 
compatible with reports the amount of gangliosides 
in rafts affects the expression and function of some 
GPI-anchored proteins (37,38) including PrP
C
 (39). 
 
Our observation that desialylated PrP
C
 remained in 
cells longer than PrP
C
 suggests that sialic acid in 
the GPI anchor affects the trafficking of PrP
C
. The 
endocytosis of PrP
C
 involves a step in which it 
moves out of rafts and enters clathrin-coated pits 
(17,40). We speculate that desialylated PrP
C
 
stabilised within cholesterol-dense rafts does not to 
move out of rafts nor undergo the same endocytic 
process as PrP
C
. It is possible that the cellular 
location of desialylated PrP
C
 results in reduced 
interactions with PrP
Sc
, which would explain why 
desialylated PrP
C
 was not converted to PrP
Sc
.  
 
Desialylated PrP
C
 also inhibited the conversion of 
endogenous PrP
C
 to PrP
Sc
 in primary cortical 
neurons, ScN2a and ScGT1 cells. Previously we 
had shown that monoacylated PrP
C
 reduced prion 
formation (9) and others have demonstrated that 
co-expression of mutant prion proteins alters the 
cellular localisation of wild type PrP
C
 and 
portioning into DRMs/rafts (41). One possibility is 
that desialylated PrP
C
 competes with endogenous 
PrP
C
 for specific partner proteins involved in 
endocytosis and that the depletion of these partner 
proteins alters the trafficking of endogenous PrP
C
 
and hence PrP
Sc
 formation. Here we explored the 
concept that the binding of desialylated PrP
C
 to 
PrP
Sc
 modifies the rafts that are involved in PrP
Sc
 
formation (3). The composition and hence the 
function of rafts is dynamic and controlled by an 
“induced fit” model (26). Since the composition of 
membranes is affected by the glycan structure of 
GPIs (29,31) then the membrane surrounding a 
complex between PrP
Sc
 and PrP
C
 (Figure 9C) 
would be expected to differ from membranes 
surrounding PrP
Sc
 and desialylated PrP
C
 (Figure 
9D). Studies in T and B cell receptor signalling 
show that the coalescence of raft outer membrane 
proteins affects the composition of the cytoplasmic 
leaflet and its association with signalling molecules 
(42-45). We propose that the binding of 
desialylated PrP
C
 to PrP
Sc
 changes the composition 
of the local membrane so that it is unfavourable for 
the conversion of PrP
C 
to PrP
Sc
.  
 
The hypothesis that the clustering of sialic acid-
containing GPIs attached to PrP leads to the 
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activation of cPLA2, a factor that promotes PrP
Sc
 
formation (21) was explored. This occurs naturally 
as a consequence of PrP
Sc
 self-aggregation and 
experimentally following cross-linkage of PrP
C
 by 
mAbs. Whereas cross-linkage of PrP
C
 activated 
cPLA2, cross-linkage of desialylated PrP
C
 had no 
affect demonstrating that sialic acid was required 
(13). Cross-linkage of a mixture of PrP
C
 and 
desialylated PrP
C
 reduced activation of cPLA2 
when compared with cross-linkage of PrP
C
 alone 
(13) indicating that homogeneity of the GPI 
anchors was critical. Notably the presence of 
desialylated PrP
C
 did not affect the activation of 
cPLA2 by PLAP indicating that it did not have a 
direct effect upon this enzyme. 
 
To understand how desialylated PrP
C
 inhibited 
activation of cPLA2 the cellular location of cPLA2 
was examined. The activation of cPLA2 causes it to 
migrate from the cytoplasm to membrane rafts 
(23). In control ScGT1 cells activated cPLA2 was 
found predominantly in rafts, and more specifically 
cPLA2 co-localised to PrP
Sc
-containing rafts (9). 
The addition of desialylated PrP
C
 caused the 
dissociation of cPLA2 from rafts. The targeting of 
cPLA2 to membranes containing their substrates 
can regulate the formation of second messengers 
such as platelet-activating factor that facilitate 
PrP
Sc
 formation (21). We propose that the density 
of sialic acid attached to GPIs is critical to the 
stabilisation and activation of cPLA2 in membrane 
rafts and that the binding of desialylated PrP
C
 to 
PrP
Sc
 changed the composition of the underlying 
membrane so that it no longer captured and 
activated cPLA2. This reduced the activation of 
cPLA2 by existing PrP
Sc
 and hindered the 
conversion of PrP
C
 to PrP
Sc
. It is noteworthy that 
desialylated PrP
C
 is surrounded by gangliosides 
than PrP
C
 which is consistent with reports that 
gangliosides inhibit the activation of cPLA2 (46-
48). 
 
Some of the PrP
C
 extracted from hamster brains 
have GPIs which did not contain sialic acid (12). 
The chemical composition of the GPI anchor is cell 
type specific (49) and the GPI anchor attached to 
PrP
C
 derived from a glial cell line (N9 cells) does 
not contain sialic acid (13). More recently we 
found that some neuronal cell lines produce 
predominantly desialylated PrP
C
 suggesting that 
these cells may be resistant to prion infection; an 
observation that may explain the different 
sensitivities of neurons to prion infection.  
 
In conclusion we show that sialic acid attached to 
the GPI affects the properties of
 
PrP
C
, altering the 
surrounding cell membrane, trafficking of PrP
C
 and 
PrP
C
-induced cell signalling. Critically the 
presence of desialylated PrP
C
 reduced the 
activation of cPLA2 and PrP
Sc
 formation in prion-
infected neuronal cells. We propose that sialic acid 
on the GPI anchor attached to PrP
C
 affects the 
membrane targeting and cell signalling that is 
conducive to its conversion to PrP
Sc
. Consequently, 
therapeutics that block the incorporation of sialic 
acid into GPI anchors could prove useful in the 
treatment of prion diseases. 
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Figure Legends 
 
Figure 1. N-linked glycans did not affect the conversion of PrP
C
 to PrP
Sc
 – (A) Immunoblot showing 
PrP
C
 (1) and deglycosylated PrP
C
 (2) separated by PAGE.  (B) The amounts of deglycosylated PrP
C
 (●) in 
fractions from C18 columns eluted under a gradient of propanol and water. (C) The amounts of PrP
Sc
 in 
ScGT1 cells treated daily with concentrations of PrP
C
 (□) or deglycosylated PrPC (■) as shown for 7 days. 
Values are means ± standard deviation (SD) from triplicate experiments performed 4 times, n=12.  
 
Figure 2. Neuraminidase removed the sialic acid from the GPI anchor attached to PrP
C
 - (A) 
Cartoon showing the putative structures of the GPI anchor attached to PrP
C
 and the desialylated PrP
C
. 
Glycan residues shown include mannose (Man), sialic acid (SA), galactose (Gal), inositol (Inos), N-acetyl 
galactosamine (GalNAc) and glucosamine (GlcN). (B) GPIs isolated from PrP
C
 (○) and desialylated PrPC 
(●) were separated by reverse phase chromatography using a C18 column. GPIs were detected with mAb 
5AB3-11 reactive with phosphatidylinositol. (C) HPTLC showing the migration of GPIs derived from 
PrP
C
 (1) or desialylated PrP
C
 (2) separated on silica 60 plates. (D) Dot blots showing the binding of mAb 
5AB3-11 (phosphatidylinositol), biotinylated concanavalin A (mannose), biotinylated S. nigra lectin 
(sialic acid) and biotinylated RCA1 (galactose) to GPI anchors isolated from PrP
C
 or desialylated PrP
C
.  
 
Figure 3. Desialylated PrP
C
 is not converted to PrP
Sc
 – (A) The amounts of PrPSc in Prnp(0/0) neurons 
pulsed with 1 ng PrP
Sc
 and incubated daily with control medium, 10 ng of PrP
C
 or 10 ng desialylated PrP
C
 
for 10 days. Values are means ± SD from triplicate experiments performed 4 times, n=12. (B) 
Immunoblots showing the amounts of β-actin and PrPSc in extracts of Prnp(0/0) neurons pulsed with 1 ng 
PrP
Sc
 and incubated daily with control medium (i), 10 ng of PrP
C
 (ii) or 10 ng desialylated PrP
C
 (iii) for 
10 days.  
 
Figure 4. Desialylated PrP
C
 inhibited PrP
Sc
 formation - (A) The amounts of PrP
Sc
 in Prnp
(+/+) 
neurons 
pulsed with 1 ng PrP
Sc
 and incubated daily with control medium (□), 10 ng of PrPC or 10 ng desialylated 
PrP
C
 (■) for 10 days. Values means ± SD from triplicate experiments performed 4 times, n=12. (B) 
Immunoblots showing amounts of β-actin and protease-resistant PrP in neurons pulsed with 1 ng PrPSc 
and incubated daily with control medium (1), 10 ng of PrP
C
 (2) or 10 ng desialylated PrP
C
 (3) for 10 days. 
(C)  The amounts of PrP
Sc
 in Prnp
(0/0)
 neurons pulsed with 1 ng PrP
Sc
 and incubated daily with control 
medium, 10 ng PrP
C
 or a combination of 10 ng PrP
C
  and 10 ng desialylated PrP
C
 for 10 days. Values are 
means ± SD from triplicate experiments performed 4 times, n=12. (D) The amounts of PrP
Sc
 in ScN2a 
cells treated daily with control medium (□) or desialylated PrPC (■) as shown for 7 days. Values are 
means ± SD from triplicate experiments performed 4 times, n=12.  (E) The amounts of PrP
Sc
 in ScGT1 
cells treated daily with control medium (□) or desialylated PrPC (■) as shown for 7 days. Values are 
means ± SD from triplicate experiments performed 4 times, n=12.  
 
Figure 5. Sialic acid on the GPI affects the composition of membrane rafts – Prnp(0/0) neurons were 
pulsed with 25 ng PrP
C
 or 25 ng desialylated PrP
C
 and homogenised in ice cold triton X-100. (A) The 
amounts of PrP
C
 (□) and desialylated PrPC (■) in membranes separated on a sucrose density gradient. 
Values are means ± SD from an experiment run in triplicate. Membrane rafts containing PrP
C
 were 
isolated by precipitation with the PrP
C
-reactive mAb 4F2. (B) Blots showing the amounts of PrP
C
 and 
desialylated PrP
C
 in immunoprecipitates. (C) The concentrations of cholesterol in precipitates from PrP
C
 
(□) or desialylated PrPC (■). Values are means ± SD from 4 precipitates, each measured in triplicate, 
n=12. *=cholesterol significantly higher than in PrP
C
 precipitates (P<0.05). (D) Gangliosides in 
immunoprecipitates from cells incubated with PrP
C
 (1) or desialylated PrP
C
 (2) separated by HPTLC on 
silica 60 plates. (E) The concentrations of gangliosides in precipitates of PrP
C
 (□) or desialylated PrPC 
(■). Values are means ±SD from 4 precipitates, each measured in triplicate, n=12.  *=gangliosides 
significantly higher than in PrP
C
 precipitates (P<0.05). 
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Figure 6. Sialic acid on the GPI anchor affects the stability of PrP
C
 – (A) The amounts of PrPC in rafts 
(DRMs) from Prnp
(0/0)
 neurons pre-treated with squalestatin as shown and pulsed with 10 ng PrP
C
 (□) or 
desialylated PrP
C (■) for 2 hours. Values are means ± SD from triplicate experiments performed 4 times, 
n=12. *=significantly less PrP
C
 in rafts. (B) There was a significant correlation between concentrations of 
cholesterol and concentrations of PrP
C (○), but not desialylated PrPC (●), in rafts derived from Prnp(0/0) 
neurons pre-treated with squalestatin and pulsed with 10 ng PrP
C
/desialylated PrP
C  
for 2 hours, Pearson’s 
coefficient=0.41, P<0.01. (C) The amounts of PrP
C
 in Prnp
(0/0)
 neurons pulsed with 10 ng of PrP
C
 (□) or 
desialylated PrP
C (■)  for 2 hours and incubated with control medium or PI-PLC for 1 hour. Values are 
means ± SD from triplicate experiments performed 3 times, n=9. *=significantly less desialylated PrP
C
 
after digestion with PI-PLC. (D) The amounts of PrP
C
 remaining Prnp
(0/0)
 neurons pulsed with 10 ng PrP
C
 
(□) or desialylated PrPC (■) measured at time points thereafter. Values are means ± SD from triplicate 
experiments performed 3 times, n=9. *=significantly more desialylated PrP
C
 remaining in neurons. (E) 
The amounts of PrP
C
 in Prnp
(0/0)
 neurons incubated for 2 hours with 10 ng PrP
C
 (□) or 10 ng desialylated 
PrP
C (■) and treated with control medium  or 5 μM glimepiride for 1 hour. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. *=significantly less PrP
C
 in neurons after treatment with 
glimepiride. 
 
Figure 7. Desialylated PrP
C
 reduces activation of cPLA2 by cross-linkage of PrP
C
- (A) The amounts 
of activated cPLA2 in Prnp
(0/0)
 neurons pre-treated with PrP
C
 (□) or desialylated PrPC (■) as shown and 
incubated with mAb 4F2. Values are means ± SD from triplicate experiments performed 3 times, n=9.  
(B) The amounts of activated cPLA2 in Prnp
(+/+)
 neurons pre-treated with desialylated PrP
C
 as shown and 
incubated with mAb 4F2. Values are means ± SD from triplicate experiments performed 3 times, n=9. 
 
Figure 8. Desialylated PrP
C
 reduced the targeting of cPLA2 to rafts - (A) The amounts of cPLA2 in 
membrane extracts separated on a sucrose density gradient from ScGT1 cells treated with control medium 
(□) or 25 ng desialylated PrPC (■). Values are means ± SD from an experiment run in triplicate.  (B) 
Immunoblots showing amounts of PrP
C
 and cPLA2 precipitated by mAb 4F2 (reactive with PrP
C
) from 
wildtype Prnp
(+/+)
 neurons treated for 3 hours with control medium or 25 ng desialylated PrP
C
.  
 
Figure 9. PrP
C
 with sialic acid may alter the underlying cell membrane – A schematic showing the 
proposed membranes surrounding PrP
C
 (A) and desialylated PrP
C
 (B) that include cholesterol, saturated 
phospholipids, unsaturated phospholipids and gangliosides. (C) Proposed interactions between PrP
C
 and 
PrP
Sc
 and its effects on the surrounding membrane including the incorporation of cPLA2 into membranes. 
(D) Proposed interactions between desialylated PrP
C
 and PrP
Sc
 and its effects on the surrounding 
membrane including gangliosides.  
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Tables  
 
Treatment Activated cPLA2 (units/10
6
 cells) 
 ScN2a cells ScGT1 cells 
None 1.0 ± 0.14 1.0 ± 0.11 
desialylated PrP
C
 0.48 ± 0.12 0.6 ± 0.18 
PLAP 3.87 ± 0.58 2.42 ± 0.28 
desialylated PrP
C
 + PLAP 3.52 ± 0.49 2.22 ± 0.29 
 
Table 1. Sialic acid in the GPI anchor affected prion-mediated activation of cPLA2 - The amounts of 
activated cPLA2 in cell extracts from ScN2a or ScGT1 cells pre-treated with control medium or with 25 
ng desialylated PrP
C
 and then incubated with 1 μM PLAP for 1 hour. Values are means ± SD from 
triplicate experiments performed 5 times, n=15. The amount of activated cPLA2 in untreated cells was 
standardised as 1 for each cell line. 
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